ATE505538T1 - Dna-vektoren - Google Patents

Dna-vektoren

Info

Publication number
ATE505538T1
ATE505538T1 AT04754961T AT04754961T ATE505538T1 AT E505538 T1 ATE505538 T1 AT E505538T1 AT 04754961 T AT04754961 T AT 04754961T AT 04754961 T AT04754961 T AT 04754961T AT E505538 T1 ATE505538 T1 AT E505538T1
Authority
AT
Austria
Prior art keywords
dna vectors
cancer
treatment
methods
present
Prior art date
Application number
AT04754961T
Other languages
English (en)
Inventor
Gregory Spies
Lynda Misher
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE505538T1 publication Critical patent/ATE505538T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AT04754961T 2003-06-09 2004-06-09 Dna-vektoren ATE505538T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47723203P 2003-06-09 2003-06-09
PCT/US2004/018529 WO2005002509A2 (en) 2003-06-09 2004-06-09 Dna vectors

Publications (1)

Publication Number Publication Date
ATE505538T1 true ATE505538T1 (de) 2011-04-15

Family

ID=33563762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04754961T ATE505538T1 (de) 2003-06-09 2004-06-09 Dna-vektoren

Country Status (8)

Country Link
US (1) US20100150968A1 (de)
EP (1) EP1639109B1 (de)
JP (1) JP4771954B2 (de)
AT (1) ATE505538T1 (de)
CA (1) CA2528094A1 (de)
DE (1) DE602004032235D1 (de)
ES (1) ES2363972T3 (de)
WO (1) WO2005002509A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2459492T3 (es) 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
MY149604A (en) 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
EP2151138A1 (de) 2007-04-30 2010-02-10 InterDigital Technology Corporation Zellenneuauswahl und weiterreichen mit multimedia broadcast/multicastdienst
US20120129770A1 (en) * 2009-06-22 2012-05-24 Rajyashri Karur Ramakrishna Novel polynucleotide molecules for enhanced gene expression
WO2012141653A1 (en) * 2011-04-15 2012-10-18 Naucler Cecilia Genetic variant of cytomegalovirus (cmv)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6518256B1 (en) * 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
EP1373524B1 (de) * 2000-10-13 2006-04-12 Chiron Corporation Fragmente der intron a von citomegalovirus

Also Published As

Publication number Publication date
EP1639109A2 (de) 2006-03-29
WO2005002509A3 (en) 2005-06-02
ES2363972T3 (es) 2011-08-22
EP1639109B1 (de) 2011-04-13
WO2005002509A2 (en) 2005-01-13
US20100150968A1 (en) 2010-06-17
JP4771954B2 (ja) 2011-09-14
JP2007506443A (ja) 2007-03-22
DE602004032235D1 (de) 2011-05-26
CA2528094A1 (en) 2005-01-13
EP1639109A4 (de) 2007-07-04

Similar Documents

Publication Publication Date Title
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EP1844077A4 (de) Dr5-antikörper und deren verwendung
TW200732349A (en) Anti-OX40L antibodies and methods using same
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
TW200611910A (en) Interferon-alpha polypeptides and conjugates
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE486931T1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
EP1738654A4 (de) Sojaproteinhaltige(s) lösung und gel
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
ATE505538T1 (de) Dna-vektoren
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
NO20053903D0 (no) Nukleotidlipidesterderivater.
ATE425962T1 (de) Peptid-deformylase-hemmer
ATE420162T1 (de) Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen
TW200504218A (en) Methods for preventing gluconoylation of proteins
NO20044186L (no) Peptid-deformylaseinhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties